Cobenfy ARISE Trial Results

[everhopeful]

Bristol Myers' Cobenfy fails to meet main goal as add-on treatment for schizophrenia

https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-cobenfy-fails-meet-main-goal-add-on-treatment-schizophrenia-2025-04-22/ April 22 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a late-stage trial studying it as an add-on treatment for schizophrenia, sending its shares down nearly 7% in after-market trade. So Cobenfy doesn’t make a difference if used with another antipsychotic.